Enzo Biochem INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Enzo Biochem, Inc. has completed its merger with Bethpage Merger Sub, Inc., becoming a wholly owned subsidiary of Bethpage Parent, Inc. and delisting its common stock.
Enzo Biochem, Inc. shareholders have approved the Agreement and Plan of Merger, paving the way for the company's acquisition.
Enzo Biochem, Inc. has entered into a definitive merger agreement to be acquired by Battery Ventures for $0.70 per share in an all-cash transaction, representing a significant premium to its recent trading price.
Enzo Biochem's Board of Directors is evaluating strategic options, including a potential sale, after receiving multiple acquisition inquiries.
Enzo Biochem, Inc. voluntarily delisted its common stock from the NYSE and began trading on the OTCQX under the symbol ENZB on April 21, 2025.
Enzo Biochem announces its intention to voluntarily delist from the New York Stock Exchange (NYSE) and move its trading to the OTCQX Best Market.
Enzo Biochem announces improved financial results for Q2 FY25, with sequential growth in revenue, gross margin, and operating profit/loss.
Enzo Biochem held its annual meeting on January 15, 2025, electing four directors, approving executive compensation, and ratifying its auditor.
Enzo Biochem has entered into a settlement agreement to resolve a class action lawsuit related to a 2023 ransomware attack, agreeing to pay $7.5 million and upgrade its data protection systems.
Enzo Biochem has received a notice from the NYSE for failing to meet minimum market capitalization, stockholders' equity, and average share price requirements.
Enzo Biochem has appointed Jon Couchman, a seasoned investment professional, to its Board of Directors and several key committees.
Enzo Biochem reported a 3% revenue increase for fiscal year 2024, improved gross margins, and announced a $0.10 per share cash dividend.
Enzo Biochem has reached a $1.73 million settlement with the state of Connecticut regarding overbilling allegations related to its former clinical services subsidiary.
Enzo Biochem has reached agreements with the Attorneys General of New York, New Jersey, and Connecticut, resolving inquiries related to a 2023 ransomware attack and agreeing to a $4.5 million settlement.
Mary Tagliaferri, M.D., has resigned from the Enzo Biochem Board of Directors, effective August 6, 2024, to pursue other opportunities.
Enzo Biochem has approved a new employment agreement for its CFO, Patricia Eckert, increasing her base salary and granting her stock options.
Enzo Biochem's CEO, Kara Cannon, has received a second amended employment agreement, effective January 1, 2024, which includes a salary increase to $400,000 and a sign-on equity grant.
8-K: Enzo Biochem Reports Strong Second Quarter with Double-Digit Revenue Growth in Life Science Division
Enzo Biochem's Life Science division saw a 14% year-over-year revenue increase in the second quarter, driven by strong demand in the drug development and cell and gene therapy markets.
Enzo Biochem has increased the base salaries of its CEO and CFO, awarded them cash bonuses, and granted them equity incentives.
Enzo Biochem has appointed Kara Cannon as CEO and Patricia Eckert as CFO, removing their interim titles, following the company's annual shareholder meeting.